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Abstract
The purposes of this study were 1) to investigate the feasibility of using optical tomography in the near-infrared
(NIR) spectrum combined with ultrasound (US) localization (NIR/US) in monitoring tumor vascular changes and
assessing tumor pathological response during chemotherapy and 2) to compare the accuracy of NIR/US with mag-
netic resonance imaging (MRI) in predicting residual cancer after neoadjuvant chemotherapy. Eleven female pa-
tients were studied during treatments with a combined imager consisting of a commercially available US system
coupled to an NIR imager. Contrast-enhanced MRI was performed before treatment and surgery. Tumor vascular
content was assessed based on total hemoglobin concentration and volume obtained from NIR data. A percentage
blood volume index (%BVI) was calculated as the percentage ratio of the product of total hemoglobin concentra-
tion and volume normalized to pretreatment values. At treatment completion, pathologic assessment revealed
three response groups: complete or near-complete responders (A), partial responders (B), and nonresponders
(C). The mean %BVIs of groups A, B, and C at the treatment completion were 29.1 ± 6.9%, 46.3 ± 3.7%, and
86.8 ± 30.1%, respectively (differences statistically significant, P< .04). At the end of cycle 2, the %BVI of group A
was noticeably lower than that of the partial (P = .091) and nonresponder groups (P = .075). Both NIR/US and MRI
were equally effective in distinguishing different response groups in this pilot study. Our initial findings indicate
that NIR/US using %BVI can be used during chemotherapy to repeatedly monitor tumor vascular changes. NIR/US
also may evaluate pathologic response during treatment allowing for tailoring therapies to response.
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Introduction
Neoadjuvant chemotherapy is being used more frequently for pa-
tients with stage II or stage III breast cancer [1]. When used before
surgery, it often allows for breast conservation by reducing tumor
size [2]. An additional benefit of neoadjuvant chemotherapy is
the opportunity to assess the chemoresponsiveness of the tumor
in vivo. Moreover, important prognostic information is obtained;
when a pathologically complete response is achieved, patients have
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increased disease-free and overall survival [3,4]. Because there are
many new agents available for the treatment of breast cancer, it is im-
portant to monitor tumor response so the best therapy can be used in
each setting [5].
Conventional methods to monitor response to neoadjuvant che-
motherapy include physical examination, ultrasonography (US),
and mammography. However, they have been shown to be only
moderately useful for predicting residual pathologic tumor size after
neoadjuvant chemotherapy [1,6]. A study comparing these three
methods in 189 patients treated with neoadjuvant chemotherapy
found all three had correlation coefficients of 0.41 to 0.42 with re-
sidual tumor [6]. More recently, magnetic resonance imaging (MRI)
has been increasingly used to evaluate neoadjuvant chemotherapy of
locally advanced breast cancers [1,7]. Several studies have assessed the
use of MRI performed early in neoadjuvant treatment for predict-
ing subsequent clinical or pathologic tumor response [8–10]. Other
studies have evaluated the residual disease after the neoadjuvant
treatment before surgery and demonstrated that lesion size measured
by MRI after treatment correlates well with residual tumor evaluated
by pathology [11,12]. However, because of the potential for false-
negative MRI determinations after neoadjuvant treatment, a phenome-
non that has been attributed to diminished contrast enhancement
due to the antiangiogenetic effect of treatment, surgery remains an
important procedure for all patients including those with no evidence
of residual disease on postchemotherapy MRI [7]. Positron emission
tomography (PET) is a promising technique both for predicting
neoadjuvant treatment at early stage [13] and for assessment of re-
sidual disease [14]. There are many ongoing studies to assess the pre-
dictive value of PET in the neoadjuvant setting [1].
Near-infrared (NIR) light between the wavelengths of 650 and
900 nm propagates deeply through tissues. Diffuse optical tomogra-
phy using NIR light provides a unique approach for functional and
molecular-based diagnostic imaging of the breast and for monitor-
ing the chemotherapeutic response of breast cancers [15–34]. The
primary limitation of diffuse optical tomography is related to the
fact that multiple scattering dominates NIR light propagation in
tissues, making three-dimensional localization of lesions and accu-
rate quantification of lesion optical properties difficult. Recently,
optical tomography guided by co-registered MRI, X-ray, and US
has demonstrated a great potential to overcome lesion location un-
certainty and to improve light quantification accuracy [26,28,29,31–
33]. We have introduced the US-guided optical tomography technique
(NIR/US), which uses co-registered US to localize breast lesions and
optical tomography to image tumor total hemoglobin (tHb) distri-
bution, which is directly related to blood vessel density in tumors.
We have shown that, on average, the tHb concentration of early-stage
malignant cancers is twice that found in benign breast lesions [31,32].
We have also observed heterogeneous tHb distributions from a small
number of patients who have advanced cancers and showed that the
distorted distributions correlate with histologic microvessel density
(MVD) counts [33]. In this article, we report our initial experience
with serial observations using NIR/US in a group of patients with
large palpable breast cancers treated with neoadjuvant chemotherapy.
A novel volumetric measurement of tHb has been introduced to quan-
titatively evaluate the treatment response. The objectives of the study
using NIR/US were to assess how tumor vasculature reacts to neo-
adjuvant treatment and to determine how well the vascular response
correlates with the tumor pathologic response. Another study objective
is to compare the vascular response measured by NIR/US with that
measured by contrast-enhanced MRI.
Materials and Methods
Subjects
The study cohort included 16 consecutive patients who were re-
ferred for neoadjuvant chemotherapy and agreed to participate in
our study. These patients were treated at the Neag Cancer Center of
the University of Connecticut from March 2004 to June 2007. The
study protocol was approved by the university institutional review
board, and signed informed consent was obtained from all patients.
Eleven of 16 patients completed the study and were repeatedly imaged
by NIR/US before initiation of chemotherapy, at intervals of two,
four, and six cycles during chemotherapy, and before definitive surgery.
Four patients did not complete the study either due to a change in
their treatment plan or due to unwillingness to continue to participate.
One patient was studied only once before her definitive surgery. Ta-
ble 1 (columns 1 to 7) presents the clinical characteristics of the final
study group. This includes assessment of tumor size by clinical exam-
ination at the initial presentation and at the completion of neoadjuvant
chemotherapy. The initial tumor depth estimated by palpation and
US is also given in Table 1 (column 3). The histologic type in 10
of these patients was invasive ductal carcinoma; one patient had a
Table 1. Physical Exam Results (Columns 2 to 3), Tumor Characteristics (Columns 4 to 7) and Surgical Pathology (Columns 8 to 9).
Patient No./Age Size (cm)/PE
Pre/Post
Depth (cm) Type Nottingham Score
(Out of 9)/Grade
ER/PR HER2 Pre Residual Tumor Response (%)/Category (A-D)
1/67 4/0 1.5 ID 8/III −/− − Microscopic foci >99/A
2/57 4/0 2.5 ID 9/III +/+ − Microscopic foci >99/A
3/66 4/0 1.5 ID 8/III −/− + None 100/A
4/54 6/0 2.0 ID 9/III +/− − 2.4 cm 70/B
5/39 2/0 2.0 ID 9/III −/− − 1.5 cm 80/B
6/55 5/0 2.0 ID 9/III −/− + 1.5 cm 70/B
7/53 NE ∼2.0 ID 8/III −/− − 5.1-cm mass with scar,
calcification, necrosis
75/B
Foci of residual invasive carcinomas,
larger foci, 0.5 cm
8/42 4/1 1.0 ID and L, post-IL 6/II +/+ + 1.2 cm 30/C
9/47 4/5 2.0 ID 5/II +/+ − 2.0 cm 5/C
10/49 3/0 1.5 ID 6/II +/+ − 1.4 cm 5/C
11/49 4/0 1.0 ID 4/I +/+ − 3.3 cm 5/C
ID indicates infiltrating ductal; IL, infiltrating lobular; PE, physical examination; NE, scar size indeterminate.
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mixed ductal and lobular carcinoma. Invasive carcinoma within the
pretreatment core biopsies was graded by using the Nottingham his-
tologic score. Estrogen receptor, progesterone receptor, and Neu-Her2/
CerbB-2 immunohistochemistry was performed on formalin-fixed,
paraffin-embedded tissue using the DakoEnvision+ (Dako Denmark
A/S, Glostrup, Denmark) detection system. The estrogen and proges-
terone receptors were scored by the modified San Antonio Scoring
system. Test for Her-2/neu gene amplification was performed by fluo-
rescence in situ hybridization technique with the PathVision HER-2
DNA probe kit from Abbott Molecular Inc. (Des Plaines, IL). The
results were reported as the ratio of HER-2/neu to CEP 17. A ratio
greater than 2.0 is considered amplification of this gene.
Nine patients were treated with anthracycline and taxane. Of the
remaining three patients, two were treated as part of a protocol con-
taining capecitabine and docetaxel (with one of the two receiving
herceptin). The remaining HER2-positive patient was treated with
carboplatin, docetaxel, and herceptin. All 11 patients received the
first cycle of neoadjuvant chemotherapy an average of 5 days (range,
0 to 21 days) after the initial NIR/US study. The average interval
between the last treatment and posttreatment NIR/US was 14 days
(range, 2 to 33 days). The average interval between posttreatment
NIR/US and surgery was 17 days (range, 1 to 46 days). Eight patients
had pretreatment MRI an average of 2 days (range, 5 to 40 days)
before the treatment and two patients who refused MRI because
of claustrophobia had pretreatment X-ray computed tomography
(CT)/PET before the treatment. One patient had pretreatment MRI
12 days after the first treatment due to scheduling problems and her
MRI data were not used for evaluation of imaging response. The
average interval between the last treatment and posttreatment MRI
was 14 days (range, 7 to 26 days). The average interval between post-
treatment MRI and surgery was 22 days (range, 7 to 48 days). Surgery
was performed after eight (n = 6), six (n = 1), and four cycles of treat-
ment (n = 4). After completion of primary chemotherapy, eight pa-
tients underwent lumpectomy and three underwent mastectomy.
NIR Imaging System, Measurements, and Imaging Algorithm
A hand-held hybrid probe was used, consisting of the commer-
cially available US transducer L12 for a Phillips IU22 system (Philips
Electronics North America Corporation, New York, NY) located in
the middle and NIR source-detector light guides (optical fibers) dis-
tributed at the periphery (Figure 1). The technical aspects of the NIR
imager developed by our group have been described in detail previ-
ously [35,36]. Briefly, our first prototype imager consisted of 12 pairs
of 780- and 830-nm laser diodes and the second prototype consisted
of one set of 690-, 780-, and 830-nm laser diodes and 3 × 1 and 1 ×
9 optical switches that delivered the light to nine source locations.
On the receiving side, 8 (first prototype) or 10 (second prototype),
3-mm-diameter light guides were used to couple reflected light to
photomultiplier tubes (R928; Hamamatsu, Shizuoka, Japan). The
total number of source and detector pairs of both systems was com-
parable and consequently achieved similar imaging quality. The
addition of the 690-nm wavelength in the second prototype was
not used in the tHb computation reported in the article but was
used in the oxygen saturation estimation (see the Discussion). The
light was delivered to each source position sequentially and reflected
light was detected in parallel from all photomultiplier tube detectors.
The entire acquisition from all source detector pairs took about 3 to
4 seconds. For each patient, co-registered US images and optical
measurements were acquired simultaneously at multiple locations in-
cluding the lesion region and a normal region of the same quadrant
as the lesion in the contralateral breast, which was chosen as the ref-
erence site. The difference between measurements obtained from the
lesion site and the reference site was the scattered field and was used
for optical imaging reconstruction. This is a standard perturbation
approach initially introduced in Ref. 37. Presumably, any changes re-
lated to normal breast tissue response to chemotherapy at each assess-
ment point was subtracted out in this approach.
Details of the dual-zone mesh optical-imaging reconstruction algo-
rithm with experimental validation have been described elsewhere
[30,36]. Briefly, the NIR reconstruction takes advantages of US locali-
zation of lesions and segments the imaging volume into a finer grid in
lesion region L and a coarser grid in non–lesion background region B. In
all images, a 0.5 cm × 0.5 cm × 0.5 cm imaging grid was used for the
lesion and a 1.5 cm × 1.5 cm × 1 cm grid was used for the background
region. The total imaging volume is chosen to be 9 × 9 × 4 (cm3). A
modified Born approximation is used to relate the scattered field Usd
measured at each source (s) and detector pair (d) to total absorption var-
iations at wavelength λ in each volume element of two regions within
the sample. The matrix form of image reconstruction is given by
½Usd M1 ¼ ½WL;WBMN ½ML;MBTN1; ð1Þ
where W L and W B are weight matrices for lesion and background re-
gions, respectively, and are calculated from the background absorption
and reduced scattering measurements acquired at the normal contralat-
eral breast. ML and MB are the to-be-determined total absorption dis-
tribution changes of lesion and background regions, respectively. The
absorption distribution at each wavelength is obtained by dividing
ML and MB with different voxel sizes in lesion and background tissue
regions. With this dual-mesh scheme, the inversion is well conditioned
and the image reconstruction converges in a few iterations.
Optical absorption distribution at each wavelength was recon-
structed and tHb distribution was computed from absorption maps
at 780 and 830 nm. Maximum and average tumor tHb concentration
(maxtHb and avetHb) were measured and the average was computed
within the volumetric zone exceeding 50% of the maximum value.
The standard full width at half-maximum (FWHM) tHb image was
Figure 1. Combined US and NIR systems and a hand-held probe
with a centrally located US linear array and NIR source-detector
fibers distributed at the periphery of the probe.
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used to measure the tumor diameter in three dimensions noted as DX,
DY, and DZ . The blood volume index (BVI) is defined as the product
of maximum diameters DX, DY, and DZ in two spatial dimensions and
in depth, and the avetHb of the tumor, i.e., BVI = DX × DY × DZ ×
avetHb. The BVI obtained before treatment is taken as the baseline for
each patient and the percentage blood volume index (%BVI) normal-
ized to the baseline is used to quantitatively evaluate the tumor blood
volume changes during chemotherapy. %BVI normalizes each individ-
ual patient’s response to pretreatment and facilitates the assessment of
changes during treatment.
US/MRI Assessment of Tumor Response
In all patients, US images were acquired and the largest tumor
sizes in spatial dimensions and in depth were measured. Breast
MRI was performed using a Siemens unit with a field strength of
1.5 T. Breast MRI images were acquired before and after 20-ml gad-
olinium injection. The precontrast sequence includes inversion re-
covery as well as T1 and T2 fat saturation images followed by a
dynamic sequence of T1-weighted images. This sequence entails
one noncontrast set immediately followed by five consecutive post-
contrast sets. Subtraction of each of the five postcontrast sets from
the precontrast set is used to evaluate lesions. The size of the tu-
mor is measured from MRI in craniocaudal (CC), transverse (T),
and anterior-posterior (AP) dimensions. One patient (patient 8)
had two lesions. As recommended in Ref. 37, the sum of the two
volumes is used as the total volume for computing the fractional
change. One radiologist (M.K.) performed these measurements while
being blinded to the optical imaging results.
Image response as measured by US and MRI was determined ac-
cording to published criteria involving changes in tumor volume after
chemotherapy [38]. The percentage reduction in volumetric mea-
surements of US and MRI is shown in Table 2. Complete response
indicated disappearance of the primary tumor, partial response in-
dicated a volume reduction of at least 65%, and progressive disease
Table 2. Imaging Findings.
Patient (Response Category) MRI CC × T × AP (cm) % Reduction US (cm) % Reduction Hb Level, Max tHb/
Ave tHb (μM/l)
Pattern FWHM (cm3) %BVI % Reduction
1 (A) CT 4.4 × 4.4 × 2.7 100 83.8/54.3 6.2 × 5.0 × 2.0 100
3.2T × 3.2AP N/A 1.5 × 1.5 × 1.2 83.3/54.6 5.0 × 5.4 × 1.5 65.7
No residual tumor mass 78.0/54.4 3.4 × 3.9 × 1.5 32.1 67.9
2 (A) 3.5 × 4 × 4 2.8 × 2.8 × 1.8 100 57.6/40.0 4.1 × 4.5 × 2.0 100
No residual tumor mass 100 1.3 × 1.3 × 0.9 47.7/32.2 3.0 × 4.5 × 2.0 58.9
0.6 × 0.6 × 0.4 34.1/23.9 3.5 × 4.8 × 1.5 40.8
No residual tumor mass 55.4/38.2 2.5 × 3.5 × 1.5 34.0 66.0
3 (A) 1.8 × 2.0 × 3.7 2.3 × 2.5 × 1.3 100 115.5/73.9 4.1 × 3.5 × 2.0 100
No residual tumor mass 100 2.5 × 2.5 × 0.3 72.5/52.1 4.0 × 5.5 × 1.0 54.0
No residual tumor mass 53.0/36.6 3.0 × 4.1 × 1.0 21.2 78.8
Ave. of group A 100 (±0) 100 (±0) 29.1 (±6.9) 70.9 (±6.9)
4 (B) CT 2.7 × 2.7 × 2.5 110.9/69.0 5.5 × 6.7 × 2 100
5.3T × 4.3AP N/A 1.9 × 1.9 × 2.0 85.6/56.3 4.0 × 4.8 × 2 42.5
2.1 × 2.1 × 1.4 89 85.0/54.6 5.3 × 4.3 × 2 48.9
1.5 × 1.5 × 0.9 72.6/46.5 4.8 × 5.4 × 2 47.4 52.6
5 (B) 3.3 × 3.3 × 2.2 109.1/72.4 3.4 × 3.4 × 2.0 100
3.3 × 4.0 × 5.4 1.9 × 1.9 × 1.2 89.3/60.9 4.7 × 4.0 × 1.5 102.6
1.3 × 1.2 × 1.0 98 1.1 × 1.1 × 0.8 94 57.0/37.0 3.5 × 4.2 × 1.5 48.7
1.4 × 1.1 × 0.9 56.9/37.9 3.5 × 4.2 × 1.5 49.9 50.1
6 (B) 3.1 × 3.1 × 2.0 74.7/48.3 4.9 × 3.9 × 2.5 100
2.7 × 2.1 × 4.4 2.6 × 2.6 × 1.6 72.7/48.3 4.0 × 5.9 × 2.0 98.8
0.8 × 1.1 × 1.0 96 1.3 × 1.3 × 0.9 98 49.0/33.0 4.5 × 5.4 × 2.0 69.5
0.8 × 0.8 × 0.6 61.5/42.0 2.9 × 4.4 × 2.0 46.5 53.5
7 (B) 5.2 × 5.2 × 3.0 131.7/86.2 5.8 × 7 × 2.5 100
4.4 × 3.7 × 2.8 5.2 × 5.2 × 3.0 134.7/89.7 6 × 5.9 × 2.5 90.7
1.2 × 1.4 × 1.2 97 4.3 × 4.3 × 2.5 40 136.6/90.8 4.5 × 4.6 × 2.5 53.7
4.4 × 4.4 × 2.5 113.8/72.8 4.5 × 4.4 × 2.5 41.2 58.8
Ave. of group B 97 (±1) 80.3 (±27.1) 46.3 (±3.7) 53.8 (±3.7)
8 (C) #1: 2.7 × 2.1 × 2.3 3.5 × 3.5 × 1.5 93.3/59.3 4.0 × 7.0 × 1.5 100
#1: 1.9 × 1.7 × 1.5 63 3.3 × 3.3 × 1.3 106.4/70.0 3.3 × 6.9 × 1.5 96.0
#2: 1.4 × 1.5 × 1.2 Sum 1.8 × 1.8 × 1.0 83 99.4/67.8 3.2 × 5.3 × 1.5 69.3 30.7
#2: 0.8 × 0.6 × 0.8 85, 66
9 (C) 3.8 × 4.0 × 2.5 152.0/98.0 4.5 × 4.5 × 2.5 100
2.8 × 2.3 × 2.8 2.9 × 2.9 × 1.8 143.3/96.4 3.5 × 4.0 × 2.5 68.0
2.0 × 1.9 × 2.1 56 2.7 × 2.1 × 2.0 70 112.8/76.0 3.5 × 4.0 × 2.5 53.6 46.4
10 (C) 2.2 × 2.5 × 1.4 72.0/49.0 3.5 × 3.6 × 2 100
N/A 2.0 × 2.0 × 1.3 72.9/49.4 3.8 × 3.6 × 2 109.5
2.0 × 2.0 × 1.3 32 67.9/44.1 4.5 × 3.6 × 2 115.7 −15.7
11 (C) 3.2 × 3.2 × 2.0 131.1/86.8 4.5 × 4 × 2 100
3.8 × 2.8 × 2.3 16 2.7 × 2.7 × 1.7 125.1/81.2 5.0 × 4.8 × 2 124.7
2.3 × 3.0 × 2.6 1.9 × 1.9 × 1.7 118.4/77.3 4.0 × 4.4 × 2 87.1
1.3 × 1.3 × 1.5 88 123.0/80.0 4.8 × 3.5 × 2 86.0
1.3 × 1.3 × 1.5 123.7/84.7 5.0 × 4.0 × 2 108.4 −8.4
Ave. of group C 46 (±26.5) 68.3 (±25.3) 86.8 (±30.1) 13.3 (±30.1)
N/A indicates not available.
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indicated a volume increase of at least 73%. Stable disease corre-
sponded to all other cases that were not in the other three categories.
Pathological Assessment of Tumor Response
In all study patients, the core and definitive surgical specimens
were previously signed out by attending pathologists as and when
the specimens were received in the department of pathology. The in-
formation about any residual tumor with gross and/microscopic mea-
surements as well as histologic evidence of necrosis, fibrosis, and
calcification, if any, was also previously documented within the pa-
thology reports. Two authors (P.H. and S.T.) compiled the tumor
responses by using the grading scale established by Sataloff et al.
[39]. The grading of pathologic response reproduced within the
breast specimens is as follows: total or near-total therapeutic effect
(grade A), more than 50% therapeutic effect but less than total or
near-total effect (grade B), less than 50% therapeutic effect but visi-
ble effect (grade C), or no therapeutic effect (grade D). Therapeutic
effect is defined by microscopic changes such as fibrosis, necrosis,
myxoid change, hemosiderin deposition, calcifications, or foamy
macrophages with or without inflammatory infiltration. A quan-
titative assessment of these changes within the definitive surgical
specimens in comparison to the needle core biopsies was expressed
as percent reduction of tumor (Table 1, column 9). These two
authors were blinded to the optical imaging results.
Histological Determination of MVD
MVD was determined within final definitive surgical specimens of
the primary tumor. The specimens were fixed as described earlier. Par-
affin sections (5 μm) were dewaxed in xylene and hydrated through
serial alcohol. The sections were stained with hematoxylin and eosin
for pathologic evaluation. One to two blocks of the tumor were se-
lected for CD31 immunostain (clone JC70A, Dako autostainer).
Block selection was preferably from the anterior and posterior portions
of the tumor to correspond to the anterior and posterior planes of tHb
concentrations measured from NIR images. Immunostained slides
were evaluated for vessel density using an ocular grid to count the ves-
sels within 10 consecutive fields of 200× magnification. Vessel counts
were performed within the areas of invasive carcinoma starting from
the highest vascular spots within the sample [40]. In patients who
demonstrated total or near-total therapeutic response, the location of
the preexisting tumor was determined by the clip. Histologically, this
area was marked by fibrosis with focal chronic inflammation. An
average of two vessel-count readings performed within a 5-mm radius
around the fibrosis was calculated and represented the MVD after
neoadjuvant therapy. One pathologist (P.H.) performed these studies
while being blinded to the optical imaging results.
Statistical Analysis
A two-sample t test with unpooled variance estimate was used to
calculate statistical significance between groups. NIR %BVI data and
US and MRI volumetric reduction data were tested for normality
first using Bera-Jarque test at the significance level of α = 0.05. Each
data set is from a normal distribution without outliers.
Results
Patient and Tumor Characteristics
The clinical characteristics of the patients and their tumors are pre-
sented in Table 1 (columns 1 to 7). None of the patients had bilateral
disease. Six of seven patients with high-grade tumors were post-
menopausal (average age, 59 years), whereas patients with all low-
to intermediate-grade tumors were premenopausal (average age,
47 years). The average size of the high-grade tumors was 4.1 cm
and that of the lower grade tumors 3.8 cm. One of 11 patients
had an indeterminate-sized tumor by examination, as her cancer re-
curred in the scar of a previously irradiated breast. She went on for
mastectomy with clear margins as is the standard of care in that set-
ting. Of the remaining 10 patients, eight had lumpectomies and two
underwent mastectomies. Both mastectomies were performed in pa-
tients with small breast size and lower grade cancers. Interestingly,
both of these patients had complete or near-complete clinical re-
sponses by physical examination. Nine of 11 patients had clinical
complete responses and one of 11 had stable disease.
Correlation of NIR/US with Pathological Response
Residual tumor evaluated from surgical pathology and the tumor
response category are given in Table 1 (columns 8 and 9). Three of
11 patients, all with high-grade tumors, had a complete or near-
complete pathologic response (group A). The tumor bed of the
near-complete responders contained a few viable tumor cells remain-
ing in a sea of stroma. Four of the remaining patients, again all grade
III, had a significant partial response with a 70% reduction in tumor
burden (group B). The four remaining patients with lower grade
tumors had a minimal to absent response (group C). These non-
responders were all estrogen and progesterone receptor positive and
had HER2-negative tumors except one case with two tumor types.
Calculated %BVI at treatment completion accurately reflects the
three groups seen pathologically (Figure 2, red bar) in this pilot study.
The mean %BVIs and standard deviations were 29.1 ± 6.9%, 46.3 ±
3.7%, and 86.8 ± 30.1% for groups A, B, and C, respectively. The %
BVI in group A is significantly lower than in B (P < .02) and C (P <
.02), whereas the %BVI in group B is significantly lower than in C
(P < .04). The mean %BVI and standard deviation of the responder
group (A + B) is 38.9 ± 10.3%, which is considerably lower than that
of nonresponders in group C (P < .04).
To assess the potential of NIR/US in predicting early response, the
%BVIs at the end of cycle 2 were reviewed (Figure 2, blue bar). The
Figure 2. %BVI obtained from complete/near-complete responder
group A, partial responder group B, and nonresponder group C at
the end of cycle 2 (blue bars) and before surgery (red bars).
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mean %BVIs and the standard deviations were 59.5 ± 5.9%, 83.7 ±
27.9, and 96.2 ± 28.4% for groups A, B, and C, respectively. The %
BVI of group A is noticeably lower than those of the partial (P =
.091) and nonresponder groups (P = .075); however, the statistical
significance is moderate. This is mainly due to the larger standard
deviations of groups B and C. There is no noticeable difference be-
tween B and C (P = .294). The %BVIs from responders (A + B) and
nonresponders obtained at the end of each treatment course were
also reviewed. The mean %BVI of the responder group (73.3 ±
23.8%) is lower than that of the nonresponder group (96.2 ±
28.4%) at the end of cycle 2; however, the statistical difference is
weak (P = .15). The mean %BVI of the responder group is signifi-
cantly lower than that of the nonresponder group at the end of treat-
ment (P = .023).
MRI/US and NIR imaging data are given in Table 2. Three types
of vascular response patterns from the chemoresponsive group (A +
B) were observed in NIR images. The first pattern was characterized
by a significant reduction in size measured by FWHM from the tHb
image, but not much reduction in tHb level or its functional activity
(Figure 3). The second pattern was characterized by a reduction in
both tHb level and size (Figure 4). Five patients in groups A and B
belong to this category. The third pattern was characterized as signifi-
cant reduction in tHb level but only a small change in size. In addi-
tion to the complex tHb patterns discussed above, two lobulated
carcinomas (patients 1 and 4) showed highly heterogeneous tHb dis-
tributions before treatment; the distribution was more uniform after
two cycles of treatment. Two of four nonresponding patients showed
no observable reduction or increase in %BVI (Figure 5). In these two
patients, both tHb level and tumor size demonstrated either no
change or an increase throughout the treatment period.
US and MRI Imaging Results
The percentage reduction in volumetric measurements of US is
shown in Table 2. The averages and standard deviations of groups
A, B, and C are 100 ± 0%, 80.3 ± 27.1%, and 68.3 ± 25.3%, respec-
tively. No statistical significance was found between groups A and B
and between groups B and C at the significance level of .05. No sta-
tistical significance was found between the responder and non-
responder groups at the same significance level. The difference
between groups A and C is significant (P < .05). If US were used
for predicting the response, three patients in group C would be mis-
classified into B, whereas one patient in group B would be in C.
The average volumetric reduction in MRI of groups A, B, and C
are 100 ± 0% (n = 2), 97.0 ± 1.0% (n = 3), and 46 ± 26.5% (n = 3).
Statistical significance was found between groups A and B (P < .02),
A and C (P < .04), and B and C (P < .04). Statistical significance (P <
.04) was found between responders (98.2 ± 1.8%, n = 5) and non-
responders (n = 3). If MRI were used for predicting response, one
patient in group C (patient 8) could be misclassified into group B.
Linear regression analysis between the volumetric reduction in
MRI and %BVI in NIR obtained a correlation coefficient of
0.914, which is statistically significant (P < .002), whereas the same
analysis between volumetric reduction in US and %BVI obtained a
correlation coefficient of 0.510, which showed no statistical signifi-
cance (P = .109).
MVD and Correlation with tHb Measurements
Figure 6 shows the MVD counts obtained from the anterior and
posterior portions of invasive carcinoma within the surgically resected
breast specimens versus measured maximum tHb at the correspond-
ing planes in the tHb images. Linear regression analysis obtained
0.4577 correlation coefficient, which is moderately significant (P =
.056). Note that for patients with residual tumors, two blocks from
the anterior and posterior portions of the tumor, which corresponded
to the anterior and posterior planes of tHb concentrations, measured
from NIR images were selected for MVD counts. One data point
obtained from a partial responder (surgery was performed at another
hospital) was an outlier and was removed to obtain the linear regres-
sion curve. The mean MVDs and standard deviations of responders
and nonresponders were 77.6 ± 23.15 and 89.8 ± 18.96, respectively.
No statistical significance was found between these two groups on
MVD at the significance level of .05.
Discussion
The objective of this study was to assess how tumor vasculature
reacts to treatment and how these changes are measured with nonin-
vasive NIR/US technology. Total hemoglobin concentration mea-
sured by this technology directly correlates to MVD, as shown in
this study (Figure 6) and in an earlier study [33]. However, we found
in this study that there was no statistical difference between respond-
ers and nonresponders in MVD. Makris et al. [41] reported lower
tumor microvessel counts in patients with breast cancer treated with
chemoendocrine therapy compared with untreated patients. How-
ever, the authors reported no statistical differences in MVD between
responders and nonresponders. %BVI is a novel way of measuring
blood vessel density, taking into consideration tHb concentration
and vessel mass by volumetric measurements. Recently, optical to-
mography has been explored by several research groups for its poten-
tial role in monitoring response to chemotherapy [18,27,33,41].
Case reports from these groups are consistent with our results re-
vealing that most responders demonstrate a reduction in tHb level
during chemotherapy. However, we found in this pilot study that
tHb or MVD does not correlate to pathologic response if volumetric
measures are not included.
All responding patients (A + B) showed a reduction in %BVI. The
reduction is never 100% but was as large as 79% in our one com-
plete responder. It is possible that the rapidly proliferating compo-
nents of the vasculature and more immature components regress,
leaving a better differentiated, more established vasculature that is
slow to regress [42]. There was no single pattern of response: some
had volume reductions without change in tHb; others had tHb re-
duction with no change in volume; others had a combination of vol-
ume and tHb reduction. This heterogeneity of response may be
explained in part by the differential chemosensitivity of the vascula-
ture or the tumor and host.
Gene expression analysis has identified three major breast cancer
subtypes [43] that have different prognoses [44]. However, a recent
study has shown that patients who had pathologically complete re-
sponse to chemotherapy had a good prognosis regardless of subtype
[45]. Thus the correlation between vascular response, as measured by
%BVI, and complete or near-complete pathologic response is very
important clinically. If one can accurately monitor response repeatedly
and as easily as performing a US exam, systemic therapy can be altered
so the most efficacious drugs could be used. Ideally, chemotherapy
should be monitored at earlier cycles as this could facilitate modifica-
tion of the regimen to enable the lesion to be maximally treated and
for the treatment response to be observed [8–10,13,34]. In a recent
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Figure 3. Ultrasound images of a high-grade infiltrating ductal carcinoma (patient 1) obtained before treatment (a1), at the end of cycle
two (a2), and before her surgery (a3). US images showed dramatic reduction of tumor size from 4.4 cm to a smaller area visible with the
assistance of a metallic marker placed before chemotherapy. (b1) to (b3) are the corresponding tHb maps. In each tHb map, seven
slices correspond to spatial images of 9 cm × 9 cm obtained starting at 0.5 cm underneath the skin surface to 3.5 cm deep toward
the chest wall with 0.5 cm spacing in depth. The color bar in tHb map is in units of micromoles per liter. The tHb map showed a het-
erogeneous pattern before treatment and was more confined to a much smaller core area at the end. (c) is a postcontrast CT scan
before initial treatment showing a lobulated tumor. (b4) displays the %BVI computed from the NIR hemoglobin images at the three
treatment points with the first point measured before treatment as the baseline. The %BVI dropped to 32.1%. This patient received
near-complete pathologic response.
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Figure 4. US images of a high-grade infiltrating ductal carcinoma (patient 3). (a1) to (a3) are US images acquired the same day before
initial treatment, at the end of cycle 2, and before definitive surgery, respectively. US images showed significant reduction in tumor volume
at the end of cycle 2. (b1) to (b3) are corresponding tHb concentrationmaps. In each tHbmap, seven slices correspond to a spatial image of
9 cm× 9 cm obtained starting at 0.2 cm underneath the skin surface to 3.2 cm deep toward the chest wall with 0.5 cm spacing in depth. A
62.5 μM/l reduction in hemoglobin level was obtained at the end of the treatment and the corresponding%BVI dropped to 21.1% (b4). (c1)
to (c2) are postcontrast subtracted MRI images acquired before initial treatment and before definitive surgery, respectively. MRI image
revealed no tumor mass at the end of the treatment. This patient received a complete pathologic response.
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Figure 5. US images of a low-grade infiltrating ductal carcinoma (patient 11) shown in the left column of (a1) to (a5). The tumor margins
shown in the first three US images were not well defined but were better delineated in the last two images (88% reduction from pre- to
posttreatment). The middle column of (b1) to (b5) shows corresponding hemoglobin maps from pretreatment (b1) to posttreatment
(B5), which reveal substantial blood volume near the chest wall (third slice) throughout the treatment. In each tHb map, seven slices
correspond to spatial a image of 9 cm × 9 cm obtained starting at 0.2 cm underneath the skin surface to 3.2 cm deep toward the chest
wall with 0.5 cm spacing in depth. (b6) plots the corresponding %BVI from baseline to preoperative assessment every two cycles and
no reduction in %BVI was observed. The left column shows postcontrast subtracted MRI images of pretreatment (c1) and posttreat-
ment (c2), respectively. Volume reduction from MRI images is 16%. This patient received a mastectomy and the pathologic residual
tumor was 3.3 × 2.8 × 1.2 cm extending to the skin and pectoralis muscle.
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study, Cerussi et al. [34] monitored 11 patients who underwent
neoadjuvant chemotherapy before and within 1 week of initial treat-
ment. The authors found that deoxygenated hemoglobin decreased
within the first week in pathologically confirmed responders, whereas
no significant change was found in nonresponders. In addition, the
measured tHb decreased in all responders. In this study, most patients
were monitored at pretreatment, cycle 2 and 4, and before surgery. No
earlier response data were obtained. However, data of complete and
near-complete responder group at cycle 2 do show a noticeable differ-
ence in %BVI than partial (B) and nonresponders (C). This suggests
that NIR/US may be sensitive enough to identify some responders at
earlier treatment cycles. Because our samples are very limited, more
patients are needed to validate these initial results.
Another important study objective was to compare vascular re-
sponse measured by NIR/US with results obtained from conven-
tional US and new imaging modality MRI. In this study, MRI was
comparable to NIR/US and was more accurate than US in distin-
guishing nonresponders from partial responders. MRI, however, is
an expensive modality to be used repeatedly during neoadjuvant che-
motherapy. In addition, some patients are also troubled by the tight
constraints of the MRI machine. However, compared with MRI,
optical systems are more cost-effective and portable for use in the
Figure 5. (continued)
Figure 6. MVD counted from anterior and deep surgical blocks of
residual tumor specimens versus tHb maximum values measured
at the top and deeper layers in the tHb images. The correlation
coefficient of linear regression curve is 0.46, which is moderately
significant (P = .0561).
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doctors’ office, and the flexible light guides can be easily coupled to
clinical US probes for repeated imaging. The limitation of our re-
ported comparison study is that only eight patients had MRI imaging
results. Nevertheless, the agreement between %BVI results and MRI
measurements in accurately classifying the different response groups
demonstrates the potential of NIR/US as a cost-effective alternative
for monitoring chemotherapeutic response.
Over the last decade, it has become known that hypoxia changes
the pattern of gene expression that alters the malignant potential of
tumors leading to more aggressive behavior and poor response to var-
ious forms of chemotherapy [46,47]. Of the 11 patients, five were
imaged with the second prototype featuring an additional wavelength
at 690 nm that is more sensitive to deoxygenated hemoglobin
changes. We observed a trend that the carcinomas were deoxygenated
before the treatment and were more oxygenated toward the end of
the treatment. No statistical difference in relative oxygen saturation
was observed between responders and nonresponders. Several reports
also indicate variable oxygenation changes during chemotherapy
[18,27,33], which are in agreement with our preliminary observa-
tions. More patient data is needed to obtain statistically valid infor-
mation on tumor hypoxia changes during chemotherapy. Hypoxia
imaging may allow better definition of a population that would bene-
fit from novel anti–hypoxia-directed therapies.
The region of interest (ROI) selection from co-registered US
image used for NIR imaging reconstruction should be noted. Optical
images were reconstructed by segmenting the volume underneath the
probe into a fine-mesh ROI and the background. Because the carci-
nomas were large in this group of patients, the entire probe size (9 ×
9 cm2) was used as the ROI in spatial dimensions. Therefore, the
reconstructed optical images were independent of tumor spatial di-
mensions seen by US. In our early phantom study [36], we found no
significant difference in reconstructed optical properties when the
ROI was twice or three times larger in spatial dimensions than a tar-
get 2 to 3 cm in size. The depth localization of NIR diffusive wave is
very poor and a tighter ROI in depth dimension is mainly set by co-
registered US and therefore depends on margins seen by US. Assisted
by chest-wall structure and normal tissue layer structures seen in co-
registered US, we can select the ROI in depth dimension reasonably
well. In general, we give at least 0.5 cm larger margin in depth than
the ultrasonically identified upper and deeper layers. In some difficult
cases with unknown margins near the chest wall, we use the chest-
wall depth as the deep margin for the ROI.
Optical imaging reconstruction is performed by using the standard
perturbation approach where the difference between the measure-
ments obtained at the lesion site and the normal contralateral site
is used as the scattered field (Usd) for inversion. Using this approach,
we could subtract any changes related to normal breast tissue re-
sponse to chemotherapy at each monitoring point. Because this ap-
proach is sensitive to contralateral site selection, we have checked
possible bilateral disease from co-registered US and MRI (if available)
and did not find any bilateral disease case in this group of patients. In
this study, the two prototype systems used have an identical design in
terms of detectors used, source power level at the fiber tips on the
probe, and electronic gains. The only differences were the addition
of a 690-nm source for better estimation of oxygen saturation and
improved system packaging for ease of transportation. Extensive
phantom studies have demonstrated comparable performance in tar-
get characterization for the two systems. In addition, %BVI is a rela-
tive measurement compared to pretreatment baseline for each patient
and it is not sensitive to minor system differences as long as the same
system is used for each patient.
%BVI is the ratio of measured BVI (product of measured tHb
volume and average tHb) at each assessment point over the pretreat-
ment baseline. Errors in tHb estimate can affect the BVI measure-
ments. One type of error is related to the quantification accuracy
of tHb. Our phantom studies showed that the estimation accuracy
for typical larger absorbers was between 55% and 101% for the typi-
cal depth we studied. However, because the %BVI is the ratio of
measured BVIs, it is less susceptible to tHb quantification accuracy.
Another type of error is related to the repeatability of the tHb quan-
tification at each assessment point. For each patient, we took several
data sets at the lesion area and the tHb and the volume reported
were average values. The mean variations from the average tHb esti-
mates for this group of patients was 2.3 μM/l, which was 4% of the
estimated tHb.
When the NIR/US technique is used to obtain the pretreatment
baseline, the data should be taken either before the patient’s diagnos-
tic core biopsy or after a certain period. A hematoma after a core
biopsy procedure could partially contribute to a higher hemoglobin
level, which could be reduced to some extent due to the normal heal-
ing process. In our study, baseline data were obtained before the core
biopsy in three patients and after in eight patients with an average of
30 days (range, 14 to 52 days). One nonresponder (patient 9) who
had her NIR/US study 14 days after core biopsy showed the highest
%BVI reduction in this group, which could be partially affected by
hematoma. The rest of the seven patients had their NIR/US study at
an average of 32 days (range, 20 to 52 days) after initial biopsy.
This pilot study has several limitations, primarily the small popu-
lation of women with locally advanced cancers. For all patients except
one, surgery was performed less than 1 month from posttreatment
NIR/US (average, 14 days) and MRI (average, 18 days). One patient
(patient 5) had a longer delay between surgery and post-NIR/US (46
days) and MRI (48 days). These intervals were similar to those of
other previously reported studies [12,48].
Our initial results have shown that NIR/US using volumetric vas-
cular measurements is a valuable tool in assessing in vivo vascular re-
sponse to neoadjuvant chemotherapy. It is a quick and noninvasive
method that may prove invaluable for neoadjuvant treatments to re-
peatedly monitor the impact of novel agents on vascular distribution.
Our initial results support the need to conduct future studies to as-
sess the value of NIR/US in the prediction of early pathologic tumor
response and residual disease before surgery.
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